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Abstract
Background: Severe malaria remains a major cause of global morbidity and mortality. Despite the use of potent
anti-parasitic agents, the mortality rate in severe malaria remains high. Adjunctive therapies that target the
underlying pathophysiology of severe malaria may further reduce morbidity and mortality. Endothelial activation
plays a central role in the pathogenesis of severe malaria, of which angiopoietin-2 (Ang-2) has recently been
shown to function as a key regulator. Nitric oxide (NO) is a major inhibitor of Ang-2 release from endothelium and
has been shown to decrease endothelial inflammation and reduce the adhesion of parasitized erythrocytes. Low-
flow inhaled nitric oxide (iNO) gas is a US FDA-approved treatment for hypoxic respiratory failure in neonates.
Methods/Design: This prospective, parallel arm, randomized, placebo-controlled, blinded clinical trial compares
adjunctive continuous inhaled nitric oxide at 80 ppm to placebo (both arms receiving standard anti-malarial
therapy), among Ugandan children aged 1-10 years of age with severe malaria. The primary endpoint is the
longitudinal change in Ang-2, an objective and quantitative biomarker of malaria severity, which will be analysed
using a mixed-effects linear model. Secondary endpoints include mortality, recovery time, parasite clearance and
neurocognitive sequelae.
Discussion: Noteworthy aspects of this trial design include its efficient sample size supported by a computer
simulation study to evaluate statistical power, meticulous attention to complex ethical issues in a cross-cultural
setting, and innovative strategies for safety monitoring and blinding to treatment allocation in a resource-
constrained setting in sub-Saharan Africa.
Trial Registration: ClinicalTrials.gov Identifier: NCT01255215
Background
Malaria is the leading parasitic cause of morbidity and
mortality worldwide, causing an estimated 240 million
clinical cases and 800,000 deaths annually [1]. Children
in sub-Saharan Africa bear the greatest burden of dis-
ease, where one in every five childhood deaths is due to
malaria and 25% of survivors of cerebral malaria develop
long-term neurocognitive impairment [1,2]. Despite the
use of highly effective anti-malarial medications, 10-30%
patients with severe malaria will die [3-5], underscoring
the need for adjunctive therapies that can be applied in
endemic areas. To date, effective adjunctive treatments
have been elusive despite numerous clinical trials [6].
New therapies, appropriate for use in endemic areas, are
therefore urgently needed to address the unacceptably
high residual mortality associated with severe malaria in
pediatric populations.
NO is a gaseous, lipid-soluble free radical that is pro-
duced in vivo by the enzymatic conversion of L-arginine
and molecular oxygen to L-citrulline by members of the
nitric oxide synthase (NOS) family of proteins. A free
radical, NO is a highly labile molecule with a half-life of
several seconds that reacts with transition metal or thiol
groups of numerous target proteins [7]. NO readily dif-
fuses across cell membranes into neighbouring cells, or
* Correspondence: kevin.kain@uhn.on.ca
1Institute of Medical Sciences, University of Toronto, Canada
Full list of author information is available at the end of the article
Hawkes et al. Trials 2011, 12:176
http://www.trialsjournal.com/content/12/1/176 TRIALS
© 2011 Hawkes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.may produce effects distant from its site of production
transported by vehicles such as low-molecular weight
S-nitrosotiols, S-nitrosylated proteins including haemo-
globin and albumin, and nitrosyl-metal complexes which
liberate NO spontaneously or after cleavage by ectoen-
zymes [8]. NO regulates numerous cellular processes
including cytoplasmic granule exocytosis, platelet aggre-
gation, endothelial-cell activation, apoptosis, inflamma-
tion, chemotaxis, neurotransmission and antimicrobial
defense by modulating the activity of regulatory proteins
[9]. A well-recognized example is the role of NO as the
endothelium-derived relaxation factor that mediates
vasodilation by activating smooth muscle soluble guany-
late cyclase (sGC) [10].
Evidence from a murine model suggests that reduced
NO bioavailability contributes to the pathogenesis of
experimental cerebral malaria [11]. “Footprint” molecules
of labile nitric oxide including cGMP and nitrite were
markedly decreased over the course of infection, and NO
supplementation with either a NO donor (dipropylene-
triamine NONOate, DPTA/NO) or NO gas provided
marked protection against severe disease [11]. Data from
human studies support the hypothesis of reduced bioa-
vailable NO in severe malaria: African children with
severe malaria have impaired production of NO [12], low
levels of mononuclear cell iNOS expression [12], low
levels of the NOS substrate arginine [13], and elevated
levels of the NOS inhibitor, asymmetric dimethyl argi-
nine [14]. Furthermore, genetic variation in NOS iso-
forms that affect plasma and urine levels of NO and its
metabolites are common in African populations and have
been shown to influence the risk of cerebral malaria
[15-19]. Factors contributing to reduced bioavailable NO
in malaria include scavenging of NO by free haemoglobin
and superoxide anion, and reduced levels of nitrate, a NO
precursor molecule [11,13,20].
The mechanism of action by which NO might improve
outcomes in malaria may involve the vascular endothe-
lium, which plays a central role in the pathogenesis of
cerebral malaria. Activation of endothelial cells is charac-
terized by increased surface expression of cellular adhe-
sion molecules, the exocytosis of Weibel-Palade bodies
(WPB), and the breakdown of intracellular tight junctions
with transudation of intravascular fluid producing end
organ dysfunction. In malaria, parasitized erythrocytes
(PEs) adhere to the microvascular endothelium, resulting
in sequestration and vascular obstruction, impaired per-
fusion and tissue hypoxia [21]. Autopsy studies in fatal
cerebral malaria reveal sequestration of PEs in the capil-
laries and post-capillary venules of multiple organs [22].
NO decreases endothelial cell adhesion molecule expres-
sion, including intercellular cell adhesion molecule-1
(ICAM-1) [23,24] and has been shown to reduce the
adherence of PEs to endothelial cells [25]. The release of
intracellular WPB contents from endothelial cells liber-
ates von Willebrand factor (vWF) [26,27] and angiopoie-
tin-2 (Ang-2) [28,29] into the circulation. Interactions of
vWF with the coagulation cascade may contribute to ves-
sel obstruction and may help tether parasitized erythro-
cytes to endothelial cells via platelets [30]. Ang-2 acts in
an autocrine and paracrine fashion to sensitize the
endothelium to the effects of TNF, resulting in increased
adhesion receptor expression [31]. In addition, Ang-2
antagonizes the interaction of the Tie-2 receptor with
angiopoietin-1 (Ang-1), thereby promoting endothelial
permeability and reducing vessel stability [32-35]. NO
inhibits the exocytosis of WPB contents through S-nitro-
sylation of critical regulatory factors [9] and may there-
fore promote endothelial quiescence, reduce vascular
fluid leak, and reduce end-organ damage. A clinical trial
demonstrated that a strategy of NO supplementation
using the NOS substrate L-arginine improved endothelial
function, as measured by reactive-hyperemia-peripheral
arterial tonometry, in Indonesian adults with moderately
severe malaria [36].
Low-flow iNO at a concentration of 5-80 ppm is
approved for use by the US FDA for the treatment of
neonates with hypoxic respiratory failure, in whom it
reduces requirements for extracorporeal membrane oxy-
genation (ECMO) and improves survival [37]. After a
decade of use in clinical practice and in numerous clini-
cal trials of iNO in critically ill older children and
adults, iNO has a well-established safety profile. Prag-
matic considerations, including a theoretically cheap
manufacturing cost and ease of administration by mask,
make NO an attractive therapeutic option for unrespon-
sive patients in resource-limited settings.
In summary, a clinical trial of adjunctive inhaled nitric
oxide (iNO) in severe malaria is warranted on the basis
of firm proof of concept from animal models [11] and a
clinical trial using the NO donor L-arginine [36],
together with evidence of safety from clinical experience
and numerous clinical trials of iNO for other conditions
[38].
Methods
Study Design
The study is a prospective, parallel arm, randomized,
placebo-controlled, blinded clinical trial of adjunctive
continuous inhaled nitric oxide at 80 ppm versus pla-
cebo (both arms in addition to standard anti-malarial
therapy), among children aged 1-10 years of age with
severe malaria. Figure 1 shows a participant flow dia-
gram for the trial, consistent with the Consolidated
Standards of Reporting Trials (CONSORT) 2010 state-
ment [39].
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Page 2 of 13Assessed for eligibility (n=...)
•Age 1-10 years
•Hospitalized for possible severe malaria
Excluded (n=...)
Not meeting inclusion criteria (n=...)
•malaria RDT negative
•no features of severe malaria
•elevated baseline metHb
•chronic illness
•severe malnutrition
•SMA alone
Declined to participate (n=...)
Other reasons (n=...)
Randomized (n=180)
Allocated to room air placebo (n≈90)
All patients receive standard antimalarial treatment
Received room air (n=...)
Did not receive room air (give reasons) (n=...)
Day 14 follow-up
Lost to follow-up (give reasons) (n=...)
Analyzed (n=...)
Excluded from analysis (give reasons) (n=...)
6-month follow-up (neurocognitive testing)
Lost to follow-up (give reasons) (n=...)
In-hospital course
Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) (n=...)
Mortality (n=...)
Allocated to iNO (n≈90)
All patients receive standard antimalarial treatment
Received iNO (n=...)
Did not receive iNO (give reasons) (n=...)
Day 14 follow-up
Lost to follow-up (give reasons) (n=...)
Analyzed (n=...)
Excluded from analysis (give reasons) (n=...)
6-month follow-up (neurocognitive testing)
Lost to follow-up (give reasons) (n=...)
In-hospital course
Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) (n=...)
Mortality (n=...)
Figure 1 Participant flow diagram. The participant flow diagram illustrates randomization of 180 children with severe malaria to inhaled nitric
oxide (iNO) or placebo, consistent with the Consolidated Standards of Reporting Trials (CONSORT) 2010 statement. RDT: rapid diagnostic test;
metHb: methemoglobin; SMA: severe malarial anemia.
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The primary objective of this trial is to compare the
longitudinal change in Ang-2, an objective and quantita-
tive biochemical marker of malaria severity, among chil-
dren who are randomized to receive inhaled nitric oxide
in addition to standard antimalarial therapy compared
to those randomized to placebo in addition to standard
antimalarial therapy.
Secondary objectives are
￿ To determine the efficacy of adjunctive iNO in
severe malaria based on clinical parameters: mortal-
ity, recovery times, length of hospital stay.
￿ To assess the effect of adjunctive iNO on labora-
tory parameters: parasite clearance, whole blood lac-
tate levels, and other biomarkers of malaria severity.
￿ To determine the efficacy of adjunctive nitric oxide
in preventing neurocognitive sequelae after severe
malaria.
￿ To assess the tolerability and safety of iNO in
severe malaria.
Study Hypotheses
The working hypothesis is that young children hospita-
lized with malaria will benefit from adjunctive iNO, as
determined by more rapid improvement in serum Ang-2
levels. We will test this hypothesis by comparing the
change in Ang-2 over the hospital admission between the
two groups randomized to receive iNO or placebo (room
air) using a mixed-effects linear statistical model.
The secondary hypotheses are that adjunctive iNO will
reduce mortality, accelerate recovery times, and shorten
length of hospital stay in severe malaria. Furthermore,
we hypothesize that iNO will accelerate improvements
in biomarkers of host response to severe malaria, includ-
ing whole blood lactate, but will not affect parasite
clearance. We hypothesize that iNO will reduce the rate
of adverse neurocognitive sequelae following severe
malaria. Finally, we hypothesize that adjunctive iNO will
be safe and well tolerated in children treated for severe
malaria.
Eligibility criteria
Children will be eligible for the trial if they meet the
following inclusion criteria:
1. Age 1-10 years
2. Positive malaria rapid diagnostic test (RDT)
3. One or more features of severe malaria: repeated
seizures (two or more generalized seizures in 24 h);
prostration (in children 1 year and older, the child is
unable to sit unsupported or stand although was
able to before the illness); impaired consciousness
(Blantyre Coma Score <5 in children 1 to 4 years,
GCS <14 for children ≥ 5 years); respiratory distress:
age related tachypnea with sustained nasal flaring,
deep breathing or subcostal retractions
4. Willing and able to complete follow up schedules
for the study - 14 day and 6 months after hospital
discharge.
The inclusion criteria require timely parasitological con-
firmation of malaria infection prior to enrolment, which
poses logistical challenges at our peripheral centre with
limited laboratory resources. For diagnosis, we will use
commercially available immunochromatographic RDTs,
complemented where possible with microscopy of periph-
eral smears. Despite well-recognized variability in the test
performance characteristics of RDTs under field condi-
tions, one commercially available RDT (First Response
Malaria Ag Combo (pLDH/HRP2), Premier Medical Cor-
poration Ltd., India) is highly ranked by the World Health
Organisation (WHO), with a 95% detection rate even at
low parasitemia and a false positive rate of 0% [40]. This
RDT includes detection bands for two P. falciparum anti-
gens, histidine-rich protein-2 (HRP-2) and parasite lactate
dehydrogenase (pLDH), and we will require positivity for
both antigens for trial inclusion. Thus, our parasitologic
criterion is expected to be highly specific, in order to
include only patients who are truly parasitemic.
The exclusion criteria for this study are as follows:
1. Baseline methemoglobinemia (>2%)
2. Known chronic illness: renal, cardiac, or hepatic
disease, diabetes, epilepsy, cerebral palsy, or clinical
AIDS
3. Severe malnutrition, defined as weight-for length
or height below -3 standard deviations based on
WHO reference charts, or symmetrical edema invol-
ving at least the feet [41].
4. Severe malarial anemia (SMA; Hb <50 g/L) with-
out other signs of severe malaria.
The latter exclusion criterion was chosen because of
differences in the pathophysiology of SMA (increased
clearance of infected and uninfected erythrocytes, and
dysregulated hematopoiesis) compared to other malaria
syndromes characterised by excessive inflammation and
endothelial activation. Based on its postulated mechan-
ism of action, it is less clear that iNO would benefit
children with SMA.
Study setting
The study will be conducted at a single pediatric hospi-
tal in Jinja, Uganda. Uganda is a low-income country
with a severely resource-constrained healthcare system.
Malaria transmission is moderate and seasonal in Jinja,
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central area of Uganda near the capital, Kampala. Jinja
Regional Referral hospital admits at least 175 children
with severe malaria annually (excluding cases of severe
malarial anemia), representing over 30% of all admis-
sions. P. falciparum resistance to chloroquine and sulfa-
doxine-pyrimethamine is widespread in the country
(34% to 67%) [42].
Treatment groups
Participants in the intervention group will receive iNO at a
concentration of 80 ppm, in addition to Ugandan standard
of care of severe malaria, which includes a potent anti-
parasitic agent. In light of the recent AQUAMAT trial
that demonstrated a mortality benefit of parenteral artesu-
nate over quinine for the treatment of African children
with severe malaria [5], artesunate will be used as the anti-
malarial of choice for this study. iNO will be administered
continuously via non-rebreather face mask for a maximum
period of 72 hours, but may be discontinued earlier if a
patient recovers and no longer tolerates the face mask.
The dose of iNO (80 ppm) was chosen as it is the highest
approved dose by the US-FDA for use in neonates, with
the greatest potential for a therapeutic effect. In pre-clini-
cal animal studies, a dose of 80 ppm provided greater pro-
tection from experimental cerebral malaria than lower
doses (Serghides, Kim, et al., unpublished data). At least
five published clinical trials across different age groups
and clinical conditions have safely used this dose [43-47].
With careful monitoring for dose-dependent adverse
events and titration of iNO concentration accordingly, a
dose of 80 ppm can safely be used in our trial.
Participants in the control group will receive room air
(indistinguishable in odour and appearance from the mix-
ture of 80 ppm iNO), in addition to Ugandan standard of
care treatment for severe malaria, including parenteral
artesunate. An air compressor will be used to deliver con-
tinuous flow of vehicle air in both groups.
Randomization and blinding methods
Simple randomization will be employed, using a compu-
ter-generated randomization list. Treatment allocation
will be recorded on paper and kept in sequentially num-
bered sealed opaque envelopes, which will be drawn for
each randomized participant by an unblinded investigator
who is not responsible for patient care, laboratory or data
analysis. We will retain all envelopes and records for
quality monitoring purposes.
In previous clinical trials using iNO, one of the design
and implementation challenges was establishing the
blinding procedures while titrating and monitoring con-
centrations of iNO, as well as anticipated dose-related
increases of methemoglobin and NO2 concentrations
[38]. The establishment of two teams, one blinded team
making all clinical assessments and therapeutic decisions,
and another unblinded team monitoring the delivery of
the treatment gas and assessing the development of
potential toxicities, allowed iNO to be delivered safely
while minimizing the possibility that direct knowledge of
treatment allocation would influence the care delivered
to the patient [38]. Thus, an unblinded investigator not
involved in patient care will be responsible for the
administration, monitoring and recording of iNO, NO2,
and methemoglobin levels. Cylinders containing NO will
be attached to the ventilation circuit in all patients, but
the flow of NO will be controlled according to treatment
arm assignment in a manner blinded to patients, care-
givers, and healthcare providers. Only the unblinded
study site investigator will administer, monitor, and
titrate the delivery of NO or placebo (room air), as well
as monitor and record the safety parameters of methe-
moglobin and NO2 levels. Laboratory analysis for Ang-2
levels (primary outcome) and all other parameter will
occur in a manner blinded to treatment allocation.
Outcome measures
The longitudinal change in serum Ang-2 concentration
over the first 72 hours of hospital admission will be the
primary efficacy endpoint. Elevated Ang-2 levels are asso-
ciated with poor clinical outcome in severe malaria [28,29]
and Ang-2 has been used to follow disease progression
and recovery in previous studies of malaria [28]. Among
survivors of severe malaria, Ang-2 levels have been shown
to decrease linearly during recovery at a mean rate of 2700
pg/mL per 24 h [28]. Thus, Ang-2 is an objective, quanti-
tative marker of disease severity, validated for longitudinal
follow-up of patients with malaria. Ang-2 levels will be
measured longitudinally at admission (day 0), day 1, day 2
and day 3 of hospitalization. Angiopoietin-2 will be mea-
sured by enzyme-linked immunosorbent assay (ELISA)
from plasma or serum samples, and is readily detectable in
samples frozen for storage and later thawed [6-9]. Com-
mercially available ELISA kits will be used (DuoSets, R&D
Systems, Minneapolis, MN). A mixed-effects linear model
will be used to compare the change in Ang-2 over time
between treatment arms.
Secondary outcomes of the trial will include relevant
clinical, laboratory and neurocognitive endpoints. We will
compare the following clinical endpoints, consistent with
other therapeutic trials for malaria [4,48,49]: mortality at
48 hours and 14 days after admission; recovery times
(time to fever resolution, time to sit unsupported); and
length of hospital stay. Parasitological outcomes including
time to parasite clearance and parasite recrudescence/re-
infection at 14 day follow-up will also be compared
between treatment groups. Biomarkers of disease severity
(in addition to Ang-2, the primary study endpoint), includ-
ing whole blood lactate, will also be followed. Lactate is
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absence of adequate tissue oxygenation, and elevated
lactate levels represent a final common pathway of tissue
hypoxia and decompensated shock, the forerunner of car-
diovascular collapse and death. We will measure lactate as
an independent biomarker of disease severity during the
clinical trial. Biomarkers of endothelial activation, inflam-
mation, and coagulopathy will also be followed as they
may provide additional insight into the pathways and pro-
cesses altered in cerebral malaria and modulated by iNO
delivery. Finally, neurocognitive outcomes in children with
severe malaria will be followed in order to determine if
adjunctive iNO may have a neuroprotective effect. The
overall cognitive deficit at 6 months after discharge will be
assessed by performing neuropsychological tests as pre-
viously described [2].
Duration of Study Participation
After admission to hospital for severe malaria, disease sur-
v i v o r sw i l lt y p i c a l l yb ed i s c h a r g e da f t e raw e e ko rl e s s .
Trial participants will be administered iNO during the
first 72 hours of admission (or less if a patient recovers
and no longer tolerates the mask), which represents the
period of highest mortality. During hospitalization,
detailed data on the interim medical history will be col-
lected, with attention to complications like coma, seizures
and hypoglycemia that might affect neurocognitive out-
come. After discharge, patients will return for a follow-up
v i s i ta t1 4d a y st ot e s tf o rP. falciparum recrudescence,
and at 6-months to undergo neurocognitive testing.
Safety
NO is approved by the US FDA for the treatment of neo-
nates with hypoxic respiratory failure, where it has been
shown to improve oxygenation, decrease pulmonary
hypertension, reduce the requirement for extracorporeal
membrane oxygenation, and improve survival [37]. In
addition, iNO is widely used in clinical practice across
North America and Europe in older children and adults
with respiratory failure, where it improves oxygenation
but has not been shown to confer a survival benefit [50].
As adjunctive therapy, iNO is safe and well tolerated in
these critically ill patient populations and a large number
of randomized controlled trials have demonstrated a
favourable safety profile of iNO. One meta-analysis of 12
trials including 1237 patients with acute lung injury or
acute respiratory distress syndrome demonstrated that
iNO is generally safe, but was associated with a statisti-
cally elevated risk of developing renal dysfunction in
these critically ill adults [38]. We anticipate that our
pediatric target population may be less susceptible to
renal injury, particularly after exclusion of patients with
underlying chronic renal disease, but we will monitor
renal function in all patients enrolled in our trial with
daily creatinine and urine output measurement.
Methemoglobinemia and elevated nitrogen dioxide
(NO2) levels in the inspiratory ventilation circuit are well-
recognized, dose-dependent, and reversible adverse effects
of nitric oxide administration; however, at doses com-
monly used in clinical practice, these are not common or
clinically important consequences [38]. Methemoglobine-
mia results from the reaction of NO with oxyhemoglobin,
thereby reducing oxygen carrying capacity [51]. NO2 is
generated from the gas phase reaction of NO with mole-
cular oxygen, and is a known pulmonary irritant [52,53].
In previous clinical trials of iNO, methemoglobin and
NO2 were routinely monitored and elevated levels consti-
tuted a criterion for NO dose reduction. Among neonates
receiving iNO at 80 ppm, 35% developed methemoglobi-
nemia (>7%) and 19% had elevated NO2 levels (>3%),
requiring reduction of the iNO concentration in the venti-
lation circuit [44]. Similarly, in our trial, methemoglobin
and NO2 will be monitored and the iNO dose will be
titrated downward according to these defined thresholds.
Furthermore, elevated baseline methemoglobinemia will
be used as an exclusion criterion from study participation
as a possible indicator of genetic susceptibility to
methemoglobinemia.
Adverse events may occur commonly in a trial involving
children with severe malaria, although the majority of
events are likely due to the clinical course of the infection
and not to study medications. For example, mortality
among Ugandan children with severe malaria receiving
standard care including potent antimalarial agents was as
high as 16% among children with impaired consciousness
and 21% among children with deep acidotic breathing as
presenting clinical signs [42]. In order to carefully and
rationally monitor the frequency of deaths in our trial for
deviations from the expected baseline level, we plan to use
statistical control charts. The control chart is a commonly
used tool to monitor output of processes in a variety of
settings, including clinical trials [54]. This method con-
tinuously follows a process outcome (e.g., patient mortal-
ity), allowing early detection of deviations from a state of
“statistical control,” thereby prompting a search for assign-
able causes. Further details of the statistical thresholds and
the performance characteristics of the control chart for
mortality in this trial are given in a supplementary file
(Additional File 1).
Other adverse events will be monitored using pediatric
toxicity tables modified from the US National Institute of
Allergy and Infectious Diseases [55]. Using this compre-
hensive checklist of potential adverse events, investigators
will grade the severity of the event and the likelihood that
the event is causally associated with the study gas accord-
ing to scales defined a priori [55,56].
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the Ugandan and North American institutions, an inde-
pendent Data and Safety Monitoring Board (DSMB) has
been convened to supervise the trial. The DSMB is com-
posed of medical and biostatistical experts with repre-
sentation from Uganda and North America who will
meet periodically and as necessary to review trial pro-
gress, safety data, and indices of study quality. Severe
adverse events, including all deaths in the trial, will be
reported in a timely fashion to the DSMB and to the
ethics boards that approved the study.
Ethical considerations
Ethical approval has been obtained from the Makerere
University Research and Ethics Committee (Kampala,
Uganda), the Uganda National Council on Science and
Technology, and the Research Ethics Board of the Uni-
versity Health Network, Toronto, Canada (REB# 10-
0607-B). The research is being conducted in accordance
with the Declaration of Helsinki.
Informed consent will be obtained from the parent/
guardian of all children that participate in the study.
Trained study team personnel will seek consent after a
comprehensive discussion with the parent/guardian of a
prospective participant in the local language (Lusoga) at
an education-appropriate level. Assent will also be sought
from those children who are alert and able to understand
the trial (age 8 and above), and sustained dissent on the
part of children will be honoured [57]. Specific aspects
included in the consent discussion include: the acuity
and potential lethality of severe malaria, residual mortal-
ity despite antiparasitic treatment, the absence of proven
effective adjunctive therapies, potential benefits and
harms of iNO, the concept of randomization and poten-
tial allocation to placebo control (although all patients
will receive standard care including potent antimalarials),
blinding of treatment allocation, blood samples required
for the trial above what is necessary for clinical care, and
the distinction between the experimental intervention
and clinical care.
International collaborative research may face complex
community challenges [58,59]. Community engagement
(CE), a participatory process of collaboration and
exchange between the various key stakeholders in the
research process, may mitigate risks with respect to trial
success, optimize participant retention, and minimize
social disruption by providing a platform to seek input
from and provide ongoing feedback to community mem-
bers [60]. There is currently no consensus on what CE
activities are required in clinical trials, but a recently pub-
lished model of CE in global health research provides a
useful framework of key CE activities and their ethical
implications [60].
We will use CE to improve awareness of our trial and
its findings in the catchment area of the Jinja Regional
Referral Hospital. We also hope the CE activities will
contribute to key ethical objectives for the trial, includ-
ing respect for communities, fairness, transparency and
accountability of the trial overall. We will focus on the
following CE activities and their associated aims: (1)
understanding the relevant c o m m u n i t yb yc onsciously
reaching out beyond the hospital to its catchment areas
and listening to their issues and concerns; (2) providing
information about the trial, including the pre-clinical
evidence behind iNO, timeframe, procedures, and what
will happen if the trial is successful; (3) building rela-
tionships and trust with local frontline healthcare work-
ers; (4) specific educational/training activities, based on
consultation with the nurses and/or frontline healthcare
workers to ascertain what would be most relevant and
beneficial for them; and (5) feedback of trial results,
guided by the community itself as to how and what
types of feedback activities would be most appropriate.
Several levels of community will be targeted, including
parents and primary caregivers of children, who com-
prise the group at highest risk of malaria, as well as
healthcare professionals within the hospital catchment
area. These activities do not constitute a mechanism for
recruitment of participants to the trial, since only chil-
dren with severe malaria will be eligible. Instead the
community engagement process is intended to build
trust and avoid misunderstandings through a dynamic
exchange of information and ideas between trial scien-
tists and community members.
Sample Size Calculation
We will enrol 180 patients (approximately 90 in each
treatment arm). To arrive at this sample size estimate,
we began with a preliminary calculation based on data
from a recent clinical data in severe malaria, in which
Ang-2 decreased by 2700 pg/mL/day (95% CI 1800-3600
pg/mL/day) [28]. We assume that a 50% change in this
parameter would represent a clinically significant thera-
peutic effect. By standard calculations for normally dis-
tributed data, 80 patients per group will provide 80%
power to detect a difference between two treatment
arms of 1350 pg/mL/day at p = 0.05 (two-sided). To
account for possible dropout, loss to follow-up, and/or
non-evaluable data of 10% of patients, approximately 90
patients per study arm are required.
To validate this preliminary sample size estimate, con-
sistent with our analytic plan (mixed-effects linear
model), a simulation study was performed. A number of
assumptions needed to be made, such as within-patient
correlation and Ang-2 variability. Patient Ang-2 data
were simulated using a multivariate normal distribution.
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with correlations of 0.75, 0.5 and 0.25 for time lags of 1,
2 and 3 days, respectively. In previous studies, variability
appears proportional to the mean [28]. Simulations were
run with three different relationships where the standard
deviation was taken to be 40%, 50% and 80% of the
Ang-2 mean at each time point. Both groups were
assumed to start at Ang-2 levels of 15,000 pg/mL [28]
and the average values at each of days 1, 2 and 3 were
based on the hypothesized slopes of Ang-2. One thou-
sand replications were performed at each standard
deviation relationship and treatment effect. The mixed
effects models were fit and the likelihood ratio test was
used to test the hypothesis of no time-by-treatment
interaction at the 5% level (two-tailed). Table 1 shows
the results of the power simulations.
Interim Analysis
An interim analysis for efficacy, safety and trial quality is
planned at the midpoint of patient enrolment (approxi-
mately 45 patients per group). There is no plan to stop the
trial prematurely for efficacy or futility based on the pri-
mary endpoint (Ang-2), other biochemical parameters,
clinical recovery times or parasitological outcomes, given
the modest size of the trial and limited statistical power at
the midpoint. Data at the time of the interim analysis will
be presented to the DSMB members for review, who may
advise that the trial continue without modification, con-
tinue with changes to the protocol, or be discontinued
prematurely. With respect to the statistical interpretation
of safety data, the DSMB may recommend termination or
modification of the trial if mortality rates exceed statistical
thresholds as described above. However, we do not pro-
pose that the DSMB be strictly bound by pre-specified cri-
teria, because of the complexity of the trade-offs between
safety, efficacy, and the possibility that new information
will change considerations. Rather, consideration of stop-
ping guidelines requires a reasoned judgment based on all
information that is available at the time of data review.
Primary Analysis
The primary focus is whether or not the rate of reduc-
tion in Ang-2 differs between the treatment groups. In
statistical terms, this is a time-by-treatment interaction.
G i v e nt h a tw ew i l lh a v er e p e a ted measurements, possi-
bly incomplete, over time, a linear mixed-effects model
will be used to estimate and test the magnitude of the
time-by-treatment interaction. A linear time trend will
not be assumed by treating “day” as a categorical vari-
able in the model. The primary analysis will be by inten-
tion-to-treat (ITT). That is, patients will be analysed in
the group to which they were randomized, regardless of
deviations from study protocol. A secondary per-protocol
analysis may be considered if important deviations from
the protocol compromise the validity of the ITT
analysis.
Secondary outcomes
Mortality
Analysis will follow standard methods in other clinical
trials for malaria [4,48,49]. Mortality at 48 h and 14
days will be coded as a binary variable. Absolute and
relative risk reduction will be reported with binomial
95% confidence intervals. Analysis will be by c
2 test or
Fisher’s exact test. In addition, we will present Kaplan-
Meier survival curves comparing patients treated with
iNO and placebo. Time to death will be analysed using
survival analysis (log-rank test for difference between
treatment arms).
Time to recovery
Among survivors (a subgroup of randomized partici-
pants), recovery times will be analysed by survival analy-
sis (log-rank test). Time to sit unsupported, time to coma
resolution (in the subset of patients with coma at study
admission) and time to discharge will be documented by
treating clinicians blinded to treatment allocation. Time
to fever resolution, defined as the time required to
achieve a temperature <38°C and the time to mainte-
nance of temperature <38°C, will be determined from fre-
quent vital sign monitoring. The time required to achieve
a reduction in parasite density of 50%, 90% and to unde-
tectable levels will be determined from daily blood
smears. Results will be expressed as the median time to
each event, with 95% confidence intervals.
Additional biomarkers (continuous variables, repeated
longitudinal measurements) will be analysed using
Table 1 Statistical power (1-b) of a trial comparing nitric oxide with placebo (n = 90 patients per group) for the
adjunctive therapy of severe malaria, using longitudinal Ang-2 levels as primary outcome
Standard Deviation of Ang-2 levels at admission (% of mean) Difference in rate of change of Ang-2 between groups
30% change
(810 pg/mL/day)
40% change
(1080 pg/mL/day)
50% change
(1350 pg/mL/day)
40 82% 97% 99%
50 66% 89% 98%
80 42% 60% 80%
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transformed value of the biomarker level as the depen-
dent variable, as appropriate.
Neurocognitive outcome
As in previous studies involving children in sub-Saharan
Africa [2], standardized instruments will be used for neu-
rocognitive testing: Kaufman Assessment Battery for
Children (working memory), the visual form of the com-
puterized Test of Variables of Attention (executive atten-
tion), and the Tactual Performance Test (tactile-based
learning). Summary variables from each test, converted
to age-specific standardized (z) scores, will provide quan-
titative measures of these three cognitive domains (work-
ing memory, attention and tactile learning). Details of
these tests are described elsewhere [2,61]. Frequencies of
overall cognitive and neurologic deficits in children trea-
ted with iNO and children receiving placebo will be com-
pared by c
2 test or Fisher’s exact test. Differences in
cognitive areas affected in the two age groups (18 mo-4
years, 5-10 years) will be assessed by comparing fre-
quency of individuals with deficits in each area by c
2 test
or Fisher’s exact test. This will also serve as the best sur-
rogate of impairment in a particular area in one age
group versus another, since the type of testing for each
cognitive area will be different for the two age groups, so
no direct comparison of level of impairment will be pos-
sible across age groups. For individual tests, age-adjusted
z-scores (determined from normative data in previous
studies among healthy community controls) will be ana-
lyzed by means of mixed-effects models to examine study
group differences in relation to neurocognitive outcomes.
The models will provide estimated mean differences
between children treated with iNO to placebo controls.
Subgroup Analyses
Although our sample size is modest, we will explore sub-
group effects by examining interaction terms in the
mixed-effects linear model. Subgroup analyses related to
important prognostic factors will be performed: age < 5
years or ≥5 years; HIV seropositivity; and bacterial co-
infection.
Quality management
Quality management (QM), both quality control and
assurance, is a continuous, ongoing process of evaluation
of the quality of the conduct and documentation of stu-
dies. The first step in QM will be training/re-training of
the research staff to ensure consistency in clinical man-
agement, sample processing and data collection. Standard
operating procedures (SOPs) have been developed for all
study related procedures and protocols, and study per-
sonnel will document any deviation from SOPs together
with the reason for the deviation. The next step for QM
will be monitoring of collected data on a prospective
basis, with daily review of source documents for comple-
teness, accuracy and consistency. Next, data entry will be
verified periodically, and discrepancies will be reviewed
with the nurses and medical officers to discover the rea-
son for errors, take corrective measures and prevent
future errors. Collection, storage and transport of clinical
samples will also be monitored on a regular basis. The
ethical conduct of the study will be monitored through
initial training in research ethics for study staff, and doc-
umentation, mediation and resolution of any perceived
violations of ethical standards by participants, their par-
ents/guardians, or members of the community at large.
Measures to minimize bias in the trial will be subjected
to formal evaluation. Quality of randomization and allo-
cation concealment will be evaluated by keeping sequen-
tially numbered opaque envelopes containing the
randomization code, which will be opened, signed and
dated at the time of randomization. Quality of trial blind-
ing will be evaluated by asking key trial persons (partici-
pants, parents/guardians, medical officers, and nurses) to
guess patients’ treatments at the end of their trial partici-
pation, and compare the answers with the actual treat-
ments, as previously described [62]. External independent
oversight of trial quality will be performed by the DSMB,
who will review trial quality indices periodically, as well
as an external trial auditor.
Discussion
Nitric oxide is an attractive candidate for an adjunctive
therapeutic agent for severe malaria given pre-clinical data
on its efficacy in animal models and an established track
record of safety in clinical practice and previous trials.
Unlike other NO donor molecules, iNO has not been
reported to cause systemic vasodilation and hypotension
[38]. Furthermore, unlike the NO precursor L-arginine,
iNO does not require functional endothelial cell NOS,
which may be compromised in patients with severe dis-
ease. It is routinely used in clinical practice as an approved
agent for hypoxic respiratory failure in neonates, and has
an established track record of safety in critically ill patient
populations. NO has been used in a wide variety of clinical
settings in older children and adults including acute
respiratory distress syndrome, pulmonary hypertension,
and pregnancy-induced hypertension [63].
Outside the existing patent, iNO is relatively inexpen-
sive [64], and can feasibly delivered by mask [47] in areas
with minimal health infrastructure. As currently mar-
keted, INOmax from INO Therapeutics is cost-effective
in high-income countries for the treatment of respiratory
f a i l u r ei nn e o n a t e s[ 6 5 ] ,b u tm a yb ep r o h i b i t i v e l ye x p e n -
sive in low- or middle-income countries. The real cost of
i N O( n o tj u s tt h ep r i c ef r o mas i n g l ec o m p a n y )i sm u c h
lower (medical grade iNO $1.99/h compared to $125/h
for INOmax) [66]. The patent for INOmax expires in
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ing and commercialization of iNO in low-income set-
tings, should iNO prove to be beneficial in severe
malaria.
Other adjunctive treatment strategies for severe malaria
previously tested in randomized controlled trials include
immunomodulation, iron chelation, reduction of oxidative
stress, anti-coagulation, volume expansion, reduction of
intracranial pressure, and prevention of seizure activity [6].
Only one agent (albumin) was associated with a mortality
benefit [6,67,68], although poor methodologic quality in
some of these trials may have limited their ability to detect
meaningful treatment effects [69]. The search for an effec-
tive adjuvant in severe malaria remains a worthwhile goal
given the significant residual mortality with primary anti-
parasitic treatment [4,5]. In this context, iNO, if demon-
strated to be effective, would represent an important
advance in malaria therapeutics.
Our hypothesis that children with severe malaria will
benefit from adjunctive iNO can be answered using a
modest sample size (n = 180). This parsimonious design
was made possible by selecting a quantitative biomarker of
malaria severity, Ang-2, as the primary endpoint and by
using a powerful statistical technique (mixed-effects linear
model). In contrast, a study using mortality (dichotomous
variable) as the primary endpoint would require a total of
over 1,000 patients to detect a 30% reduction from the
baseline mortality of 20% with 80% power, likely necessi-
tating multicentre recruitment over several years and
monumental resources. Ang-2 is a surrogate but well vali-
dated measure of malaria severity, appropriate for an early
efficacy trial in a human population. Repeated longitudinal
measurement of Ang-2 allows for increased precision in
the quantitative outcome variable, thereby reducing the
necessary sample size. The analytic plan, a mixed-effects
linear statistical model, includes random-effect terms,
appropriate for representing clustered and therefore
dependent data arising when data are gathered over time
on the same individuals [70]. We performed a computer
simulation study to validate our sample size estimate using
assumptions based on previous studies of Ang-2 in severe
malaria. In 9,000 simulated trial outcomes under different
assumptions for the treatment effect size and baseline
variability in Ang-2, the mixed-effects linear model
detected a significant treatment effect with >80% power
under most plausible scenarios. This ap r i o r ipower calcu-
lation provides further refinement on a crude sample size
calculation and provides additional evidence that the
planned number of patients is adequate to test our
hypothesis. This sample size validation is particularly
important in light of a review highlighting that numerous
previous trials of adjunctive treatments for cerebral
malaria had insufficient statistical power to detect even
large treatment effects [69].
Some unique aspects of our trial relate to its setting in a
peripheral, resource-constrained pediatric hospital in sub-
Saharan Africa. Standard clinical investigations including
quality-controlled microscopy, biochemistry and micro-
biology, as well as equipment to monitor gas delivery (NO,
NO2 and methemoglobin monitoring) need to be intro-
duced to the facility for the trial. A commercially available
portable biochemistry instrument (i-STAT
®, Abbott Point
of Care Inc., Princeton, NJ) and a pulse CO-oximeter for
non-invasive methemoglobin monitoring (Masimo Rad-
57™, Masimo Corporation, Irvine, CA) will allow for
onsite monitoring of critical investigations, with outsour-
cing of other clinical testing to reference laboratories in
Kampala. Objective qualitative determination of parasite-
mia at presentation for the purposes of trial enrolment
using commercially available lateral flow immunochroma-
tographic tests for parasite antigen detection (rapid diag-
nostic tests) will be used to supplement local microscopy,
which may be subject to error in the absence of rigorous
laboratory quality control [71]. While upgrading hospital
capacity for our trial requires the infusion of considerable
resources, it is hoped that this will result sustained local
capacity development in clinical management, laboratory
diagnostics, modern therapeutics, and innovation at the
Jinja Regional Referral Hospital, consistent with the ethical
objectives of our trial.
The cross-cultural setting of the trial poses certain ethi-
cal challenges, demanding a sensitive approach to the
informed consent process. While some of these ethical
considerations are of a universal nature, others may be
more specific to the sub-Saharan African context. First,
t h et r i a li n v o l v e sav u l n e r a b l ep e d i a t r i cp o p u l a t i o nw i t h
surrogate decision-makers. In addition to parent/guardian
consent in the local and education-appropriate language,
we have built in a second assent process for competent
participants, given that children may legitimately and
autonomously participate in decisions related to their own
healthcare [57,72]. Next, the acuity and lethality of the
underlying infection demand that consent be obtained
early after admission for maximal treatment benefit, yet
must not interfere with the emergency management of cri-
tically ill participants and must give adequate time for
stressed parents/guardians to give due consideration
before consenting. The complexity of the scientific design
(randomized, placebo-controlled adjunctive therapy, with
blinding of treatment allocation) together with variable
education level and familiarity with biomedical research of
parents/guardians presents difficulties requiring careful
explanation during the consent discussion (e.g., conveying
the position of scientific equipoise in order to accept pos-
sible randomization to placebo). Additional ethical consid-
erations which may be more specific to the African
context include the “therapeutic misconception,” (partici-
pants may not clearly distinguish research from health
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quently express concern about blood taking, including
fears about the misuse of the blood, unauthorized testing
for HIV, long-term storage, genetic testing, and harm to
the child from excessive blood loss [73]. Our consent pro-
cess explicitly addresses the distinction between study and
clinical interventions, as well as detailed descriptions of
volumes, frequency and subsequent handling of blood
samples in the trial. Finally, we have incorporated a com-
munity engagement (CE) plan into our trial design to fos-
ter a trusting relationship with the surrounding catchment
population.
Monitoring patient safety in a trial involving critically ill
children in a resource-limited environment poses addi-
tional challenges. The administration of study gas will be
tightly regulated and monitored with state-of-the-art tech-
nology, with particular attention to two dose-dependent,
reversible adverse effects: elevated inspired NO2 and
methemoglobinemia. Strict criteria for study gas disconti-
nuation have been established. Standardized pediatric toxi-
city tables will be used to monitor for other adverse events
in a blinded and objective manner. We will also monitor
mortality using statistical control charts, in order to
rationally detect deviations from the expected baseline
mortality of 20% [42,75]. This approach involves striking a
balance between the earliest detection of elevated mortal-
ity in order to institute corrective measures (“true alarm”),
and the risk of halting the trial unnecessarily for variations
in mortality due to chance alone (“false alarm”). The
upper control limit of mortality that will prompt a safety
review has thus been defined using statistical principles,
together with the predicted performance of this surveil-
lance strategy (Additional File 1). Trial safety oversight
will ultimately be provided by an independent DSMB who
will meet regularly to review recruitment, interim evidence
of efficacy, safety and trial quality.
Limitations of this trial design include its use of a sur-
rogate marker, Ang-2, as the primary endpoint. This
allows for an efficient design but may be less compelling
to clinicians than would a demonstrable mortality bene-
fit (of note, mortality has been included as a secondary
trial endpoint). On the other hand, Ang-2 has been
extensively validated as an objective and quantitative
biomarker of malaria severity [28,29,76,77]. Thus, Ang-2
is an appropriate endpoint for an initial efficacy study of
iNO in a human population, but a promising treatment
effect would require validation in costly, large, multicen-
tre trials. Blinding presents a challenge for a gaseous
therapy requiring monitoring for dose-dependent toxici-
ties, which we have addressed by separating study tasks
between a blinded team (responsible for clinical care,
assessment of endpoints and laboratory testing) and an
unblinded team (responsible for administering treatment
and monitoring safety parameters) to minimize potential
bias. Risks and costs related to conducting the study in
a resource-constrained setting are balanced with poten-
tial benefits in terms of local capacity building, the high
incidence of severe malaria allowing timely completion
of the study, and applicability of the therapy in other
malaria-endemic areas.
In summary, based on compelling data supporting the
efficacy of iNO in experimental cerebral malaria in ani-
mal models, coupled with the documented safety of
iNO in clinical practice and trials for other diseases, we
have outlined a protocol for a randomized clinical trial
of iNO for the adjunctive treatment of severe malaria in
Ugandan children. If our study demonstrates a signifi-
cant treatment effect, this would represent a major and
important advance in the treatment of severe malaria
with broad potential for global public health impact.
Additional material
Additional file 1: Details of a process control chart to monitor
mortality. This Microsoft Word file provides details of the statistical
thresholds and the performance characteristics of a statistical control
chart to monitor mortality in this trial of critically ill children.
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